NCT04082780View on ClinicalTrials.gov

Rifamycin in Minimal Hepatic Encephalopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

April 28, 2023

Study Completion Date

April 28, 2023

Conditions
Hepatic EncephalopathyCirrhosis, Liver
Interventions
DRUG

Rifamycin SV MMX

Intervention arm

OTHER

Placebo

Placebo arm

Trial Locations (1)

23249

Hunter Holmes McGuire VA Medical Center, Richmond

All Listed Sponsors
lead

Hunter Holmes Mcguire Veteran Affairs Medical Center

FED

NCT04082780 - Rifamycin in Minimal Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter